TH
Takanori Hidaka
Tohoku University
Research areas: Medicine · Oncology · Cancer Immunotherapy and Biomarkers · Cutaneous Melanoma Detection and Management · Dermatology and Skin Diseases
0009-0003-5028-5681
Employment
-
Tohoku University Assistant Professor2022 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (46)
- Additive associations of variants at the expression quantitative trait loci of TFR2 and EPO in a linkage disequilibrium block with hypochromic erythropoiesis Save
- Cohort Profile Update: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study) 2023 update Save
- Profiling of runs of homozygosity from whole-genome sequence data in Japanese biobank Save
- Simulating Metabolic Pathways to Enhance Interpretations of Metabolome Genome-Wide Association Studies Save
- Simulating metabolic pathways to enhance interpretations of metabolome genome-wide association studies Save
- Skin health survey on atopic dermatitis among Japanese children: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study Save
- Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs Save
- Chronological changes of skin eruptions toward cold abscess formation in hyper-immunoglobulin E syndrome Save
- Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients Save
- Environmental pollutants and the immune response Save
- Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma Save
- Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers Save
- BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials Save
- Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies Save
- Malassezia-derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra-mammary Paget's disease Save
- Successful treatment of unresectable advanced melanoma by administration of nivolumab with ipilimumab before primary tumor resection Save
- GITR cosignal in ILC2s controls allergic lung inflammation Save
- HLA-DRB1*04:05 in two cases of Vogt–Koyanagi–Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy Save
- Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma Save
- Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: A pilot study Save